

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waiver under 18 U.S.C. §208(b)(3)

Henry Black, M.D.

Committees: Cardiovascular and Renal Drugs and the Drug Safety and Risk Management
Advisory Committees

Meeting Date: September 12, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to all official matters concerning clinical data for New Drug Application (NDA) 020-304, aprotinin injection (trade name, Trasylol), sponsored by Bayer Pharmaceuticals Corporation, a part of Bayer HealthCare AG, a subsidiary of Bayer AG., I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Speaker's Bureau	Competitor	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

_____/S/_____
Signature of SGE

_____/08/16/07_____
Date